Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients

Overview

Homologous recombination deficiency (HRD) is an important molecular biomarker for Poly (ADP-ribose) polymerase inhibitors (PARPi) which is a significant progress in the treatment of ovarian cancer. However, the proportion of HRD positive in real world and relationship of HRD status with PARPi in Chinese ovarian cancer patients remains unknown.

Full Title of Study: “Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: the First Real-word Evidence From China”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: September 2022

Detailed Description

This study intends to perform HRD testing of ovarian cancer in real world from China and correlate HRD status and clinical characteristics with therapeutic outcomes.

Interventions

  • Drug: PARP inhibitor
    • Ovarian/fallopian tube/primary peritoneal cancer patients with PARP inhibitors according to the NCCN guideline and their instructions

Arms, Groups and Cohorts

  • ovarian/fallopian tube/primary peritoneal cancer patients
    • ovarian/fallopian tube/primary peritoneal cancer patients treated with PAPRi for more than four weeks

Clinical Trial Outcome Measures

Primary Measures

  • Overall Response Rate (ORR)
    • Time Frame: Through study completion, an average of 1 year
    • ORR is defined as the proportion of participants achieving complete response (CR) or partial response (PR) as assessed by RECIST1.1.
  • Progression Free Survival (PFS)
    • Time Frame: Through study completion, an average of 1 year
    • PFS is defined as the time in months from the date of first study drug administration to the date of first documentation of progressive disease (PD) or death as assessed by RECIST1.1.

Participating in This Clinical Trial

Inclusion Criteria

1. Subjects join the study voluntarily and sign informed consent; 2. Female subjects are older than 18 years; 3. ECOG(Eastern Cooperative Oncology Group) physical status score is 0-2; 4. Life expectancy‚Č•3 months; 5. Histologically confirmed FIGO(International Federation of Gynecology and Obstetrics ) III/IV ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; Participants must have high-grade serous or endometrioid histology; 6. Patients received PARP inhibitor as maintenance therapy or monotherapy for more than four weeks. Exclusion Criteria:

1. Personnel involved in the formulation or implementation of the research plan; 2. Patient participated in other clinical trails using other experimental drugs at the same time as the study; 3. The subjects had other malignant diseases in past 2 years, except skin squamous cell carcinoma, basal-like carcinoma, breast intraductal carcinoma in situ, or cervical carcinoma in situ; 4. Previous or currently diagnosed myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML); 5. Patients who are pregnant or lactation, or who plan to become pregnant during study treatment.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Xiaoxiang Chen
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Xiaoxiang Chen, Academic secretary of gynecological oncology Committee of Jiangsu anti cancer association – Jiangsu Cancer Institute & Hospital
  • Overall Official(s)
    • Xiaoxiang Chen, MD,PhD, Study Chair, Jiangsu Cancer Institute & Hospital
  • Overall Contact(s)
    • Jing Ni, MD, +86 13327833586, nijingwulin@126.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.